Why do IVD drug screening immunoassays report higher unconfirmed positive rates than TLC? Sensitivity Explained

The higher unconfirmed positive rate is not a sign of immunoassay inaccuracy, but a direct consequence of superior analytical sensitivity. When an in vitro diagnostic (IVD) immunoassay like an EMIT test for cocaine or amphetamines is benchmarked against thin-layer chromatography (TLC), the immunoassay consistently flags more samples as positive. These “unconfirmed” results do not mean the immunoassay is wrong. They arise because the immunoassay detects drug concentrations that fall well below the TLC method’s detection floor—concentrations that are still a true indicator of substance use.

The central insight is that an “unconfirmed positive” in this context is typically a true positive that TLC cannot see. The immunoassay’s lower limit of detection reveals real drug presence that the older, less sensitive TLC method misses entirely, which explains the discrepancy while preserving the immunoassay’s diagnostic reliability.

Sensitivity: The Core Driver of the Discrepancy

Every drug screening result lives or dies by a method’s ability to “see” the target molecule at low levels. The gap between immunoassays and TLC is almost entirely a sensitivity story.

The Cutoff Concentration Cliff

Immunoassays and TLC operate at fundamentally different sensitivity thresholds. An EMIT cocaine assay typically uses a cutoff for benzoylecgonine at 0.5 – 2.0 µg/ml, while TLC methods often require 3 – 5 µg/ml to produce a reliable visual spot. That’s a 3- to 10-fold difference in what each technique can physically detect.

How Low-Concentration Samples Create “Unconfirmed” Positives

Imagine a urine sample with 1.5 µg/ml of benzoylecgonine. The immunoassay will correctly report it as positive because it exceeds the 0.5 µg/ml cutoff. When the same sample is run on TLC, the result is negative—the analyte is simply too dilute to form a visible band. This sample becomes an “unconfirmed positive” in the benchmark, even though both the immunoassay result and the underlying pharmacology are real.

The Numbers Tell the Same Story

Real-world comparison data confirm this pattern. For amphetamine and cocaine immunoassays, the overall unconfirmed positive rate against TLC ranges from 2.6% to 12.5%, yet the false-negative rate sits near 0% to 2.3%. The vast majority of unconfirmed positives occur in the narrow concentration band between the immunoassay cutoff and the TLC detection limit—exactly where we’d expect.

Why “Unconfirmed” Does Not Mean “False Positive”

Labeling an immunoassay result as a false positive simply because TLC did not confirm it is a critical misinterpretation. The burden of proof falls on the less sensitive method, not the screening tool.

True Positives in Disguise

The primary reference makes this explicit: urine samples containing benzoylecgonine at ≤ 3 µg/ml yield true positive immunoassay results that go unconfirmed. The analyte is present and structurally intact; TLC just lacks the analytical horsepower to see it. This is a case of detection failure on the TLC side, not a specificity failure on the immunoassay side.

Preserving Diagnostic Reliability

Despite the higher unconfirmed rate, EMIT immunoassays maintain 87% to 95% total true results overall. Critically, the near-zero false-negative rate makes them ideal for screening—if a sample is truly negative, the immunoassay almost never calls it positive. The small fraction of unconfirmed samples simply requires a more sensitive confirmatory test to resolve the ambiguity.

Supporting Evidence from Other Assays

The pattern holds across multiple immunoassay formats. In morphine screening studies, EMIT, radioimmunoassay (RIA), and hemagglutination inhibition (HI) all produce substantially more positives than TLC at a 0.5 µg/ml cutoff, while false-negative rates relative to TLC remain at 1.0% or less. The “excess” positives are not random noise; they are low-concentration true drug signals.

Understanding the Trade-offs

No screening method is perfect. The sensitivity advantage of immunoassays brings real operational implications that diagnostic developers and laboratories must manage.

The Screening-Cascade Burden

A more sensitive screen will naturally generate more initial positives that require confirmatory testing. When TLC is used as the confirmatory method, a small but predictable fraction of samples will consume resources only to come back as “not confirmed” due to TLC’s limited sensitivity, not due to immunoassay error.

The False-Negative Safety Net

The trade-off is overwhelmingly worth it because the alternative—a less sensitive screen—misses true drug use. A 0% to 2.3% false-negative rate means immunoassays catch nearly every case of recent exposure, which is the entire purpose of a screening test in clinical and forensic settings. Accepting a slightly higher unconfirmed rate is the price of that near-perfect detection.

When Cross-Reactivity Is Not the Culprit

Important nuance: the elevated unconfirmed rates described here are not driven by antibody cross-reactivity. While cross-reactivity can occasionally cause false positives, the systematic discrepancy against TLC is overwhelmingly explained by the sensitivity gap for the target analyte itself. The primary reference data show the effect is concentration-dependent and reversible when a more sensitive confirmatory method is used.

Making the Right Choice for Your Screening Program

Your optimal approach depends on your core goal. Sensitivity benchmarks guide the selection of both screening reagents and confirmatory workflows.

• If your primary focus is maximum detection of substance use: Accept the higher unconfirmed rate as a marker of superior sensitivity. Use an immunoassay with a low cutoff (e.g., 0.5 µg/ml for cocaine metabolite) and pair it with a highly sensitive confirmatory method like GC-MS or LC-MS/MS to resolve all true positives.
• If your primary focus is minimizing confirmatory testing volume: Slightly raising the immunoassay screening cutoff can reduce the number of low-concentration positives that TLC would miss. However, this must be weighed carefully against the risk of introducing false negatives into a safety-critical screening program.
• If your primary focus is method validation and reagent selection: Benchmark your immunoassay against a technique with detection limits that match or exceed the immunoassay’s analytical range. Comparing a high-sensitivity immunoassay to a low-sensitivity TLC will always inflate “unconfirmed” rates, masking the true diagnostic performance.

The higher unconfirmed positive rate is not a flaw to be fixed—it is a predictable and protective feature of a highly sensitive immunoassay, one that keeps real drug use from slipping through the cracks.

Summary Table:

Developing high-sensitivity drug screening assays or optimizing your diagnostic performance? CamelBio provides diagnostic manufacturers, clinical laboratories, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—covering every stage of development from concept to clinic. Contact us today to learn how we can support your immunoassay development!